Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 2, 2016, Pages 195-206

  de Koning, Coco ^a   Plantinga, Maud ^a   Besseling, Paul ^a   Boelens, Jaap Jan ^a   Nierkens, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Allogeneic hematopoietic cell transplantation; Biomarkers; Immune reconstitution; Pediatric patients; Secretome; Serotherapy

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CELL SUBPOPULATION; CHILD; CYTOKINE PRODUCTION; DENDRITIC CELL; GAMMA DELTA T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPETENT CELL; MONOCYTE; NATURAL KILLER CELL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PASSIVE IMMUNIZATION; PRESCHOOL CHILD; PROCEDURES; RISK FACTOR; TRANSPLANTATION CONDITIONING;

BIOLOGICAL MARKER;

BIOMARKERS; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNIZATION, PASSIVE; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84958648938     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.08.028     Document Type: Review

References (109)

1. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
2. Ferrara J.L.M., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
3. Majhail N.S., Rizzo J.D. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant 2013, 48:1145-1151.
4. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006, 12:1047-1055.
5. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128-135.
6. Melenhorst J.J., Tian X., Xu D., et al. Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. Haematologica 2012, 97:867-873.
7. Olkinuora H., von Willebrand E., Kantele J.M., et al. The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol 2011, 73:586-593.
8. Lindemans C.A., Chiesa R., Amrolia P.J., et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2013, 123:126-132.
9. Booth C., Lawson S., Veys P. The current role of T cell depletion in paediatric stem cell transplantation. Br J Haematol 2013, 162:177-190.
10. Booth C., Veys P. T cell depletion in paediatric stem cell transplantation. Clin Exp Immunol 2012, 172:139-147.
11. Bosch M., Dhadda M., Hoegh-Petersen M., et al. Immune reconstitution after antithymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012, 14:1258-1275.
12. Moretta A., Maccario R., Fagioli F., et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001, 29:371-379.
13. Oshrine B.R., Li Y., Teachey D.T., et al. Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood. Biol Blood Marrow Transplant 2013, 19:1581-1589.
14. Rénard C., Barlogis V., Mialou V., et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol 2010, 152:322-330.
15. Bartelink I.H., Belitser S.V., Knibbe C.A., et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 2013, 19:305-313.
16. Kook H., Goldman F., Padley D., et al. Reconstruction of the immune system after unrelated or partially matched T cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996, 88:1089-1097.
17. Godthelp B.C., van Tol M.J., Vossen J.M., van Den Elsen P.J. T cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T cell repertoires. Blood 1999, 94:4358-4369.
18. Niehues T., Rocha V., Filipovich A.H., et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children - a Eurocord analysis. Br J Haematol 2001, 114:42-48.
19. Chiesa R., Gilmour K., Adams S., et al. Omission of in vivo T cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012, 156:656-666.
20. Charrier E., Cordeiro P., Brito R.M., et al. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transplant 2013, 48:376-382.
21. Thomson B.G., Roberston K.A., Gowan D., et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood 2000, 96:2703-2711.
22. Giraud P., Thuret I., Reviron D., et al. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience. Bone Marrow Transplant 2000, 25:53-57.
23. Klein A.K., Patel D.D., Gooding M.E., et al. T cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant 2001, 7:454-466.
24. Fagnoni F.F., Oliviero B., Giorgiani G., et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 2004, 104:281-289.
25. Vakkila J., Thomson A.W., Hovi L., et al. Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft-versus-host disease. Bone Marrow Transplant 2005, 35:501-507.
26. Horváth R., Budinský V., Kayserová J., et al. Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: Implications for the development of acute graft-versus host disease. Clin Immunol 2009, 131:60-69.
27. Eyrich M., Leiler C., Lang P., et al. A prospective comparison of immune reconstitution in pediatric recipients of positively selected CD34+ peripheral blood stem cells from unrelated donors vs recipients of unmanipulated bone marrow from related donors. Bone Marrow Transplant 2003, 32:379-390.
28. de Vries E., van Tol M.J., van den Bergh R.L., et al. Reconstitution of lymphocyte subpopulations after paediatric bone marrow transplantation. Bone Marrow Transplant 2000, 25:267-275.
29. Clave E., Lisini D., Douay C., et al. Thymic function recovery after unrelated donor cord blood or T cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. Front Immunol 2013, 4:54.
30. Reubsaet L.L., de Pagter A.P., van Baarle D., et al. Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease. Bone Marrow Transplant 2013, 48:502-507.
31. Foot A.B., Potter M.N., Donaldson C., et al. Immune reconstitution after BMT in children. Bone Marrow Transplant 1993, 11:7-13.
32. Kalwak K., Gorczyríska E., Toporski J., et al. Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery. Br J Haematol 2002, 118:74-89.
33. Parkman R., Cohen G., Carter S.L., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:919-927.
34. Inoue H., Yasuda Y., Hattori K., et al. The Kinetics of immune reconstitution after cord blood transplantation and selected CD34+ stem cell transplantation in children: comparison with bone marrow transplantation. Int J Hematol 2003, 77:399-407.
35. Koehl U., Bochennek K., Zimmermann S.Y., et al. Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival. Bone Marrow Transplant 2007, 39:269-278.
36. Bae K.W., Kim B.E., Koh K.N., et al. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children. Korean J Hematol 2012, 47:44-52.
37. Kim H.O., Oh H.J., Lee J.W., et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation in children: a single institution study of 59 patients. Korean J Pediatr 2013, 56:26-31.
38. Elze M.C., Ciocarlie O., Heinze A., et al. Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation. Bone Marrow Transplant 2014, 50:266-273.
39. Cela M.E., Holladay M.S., Rooney C., et al. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant 1996, 17:243-247.
40. Willemsen L., Jol-van der Zijde C.M., Admiraal R., et al. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant 2015, 21:473-482.
41. Scarselli A., Di Cesare S., Capponi C., et al. Longitudinal evaluation of immune reconstitution and B cell function after hematopoietic cell transplantation for primary immunodeficiency. J Clin Immunol 2015, 35:373-383.
42. Atkinson K., Biggs J.C., Downs K., et al. GM-CSF after allogeneic BMT: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust N Z J Med 1991, 21:686-692.
43. Bensinger W.I., Clift R., Martin P., et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996, 88:2794-2800.
44. Cooper M., Fehniger T.A., Caliqiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
45. Calandra T. Macrophage migration inhibitory factor and host innate immunoresponses to microbes. Scand J Infect Dis 2003, 35:573-576.
46. Matsuwaka A., Hogaboam C., Lukacs N.W., Kunkel S.L. Chemokines and innate immunity. Rev Immunogenet 2000, 2:339-358.
47. Ziegler-Heitbrock L., Ancuta P., Crowe S., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
48. Passlick B., Flieger D., Ziegler-Heitbrock H.W. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989, 74:2527-2534.
49. Döring M., Cabanillas Stanchi K.M., Haufe S., et al. Patterns of monocyte subpopulations and their surface expression of HLA-DR during adverse events after hematopoietic stem cell transplantation. Ann Hematol 2014, 94:825-836.
50. Döring M., Rohrer K.M., Erbacher A., et al. Human leukocyte antigen DR surface expression on CD14+ monocytes during adverse events after hematopoietic stem cell transplantation. Ann Hematol 2015, 94:265-273.
51. Dzionek A., Fuchs A., Schmidt P., et al. BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000, 165:6037-6046.
52. Stenger E.O., Turnquist H.R., Mapara M.Y., Thomson A.W. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012, 119:5088-5103.
53. Heinze A., Elze M.C., Kloess S., et al. Age-matched dendritic cell subpopulations reference values in childhood. Scand J Immunol 2013, 77:213-220.
54. Rajasekar R., Mathews V., Lakshmi K.M., et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol Blood Marrow Transplant 2008, 14:344-350.
55. Watanabe N., Narita M., Furukawa T., et al. Kinetics of pDCs, mDCs, gdT cells and regulatory T cells in association with graft versus host disease after hematopoietic stem cell transplantation. Int J Lab Hematol 2011, 33:378-390.
56. Guan S., Li Q., Liu P., et al. Umbilical cord blood-derived dendritic cells loaded with BGC823 tumor antigens and DC-derived exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumor immunity in vitro and in vivo. Centr Eur J Immunol 2014, 39:142-151.
57. Morita C., Ness-Schwickerath K., Nam K., et al. Innate memory of human Vγ2Vδ2 T cells: Distinct proliferative, migratory and tumorcidal capabilities of γδ memory subsets. J Immunol 2012, 188.
58. Lamb L.S., Lopez R.D. Gammadelta T cells: a new frontier for immunotherapy?. Biol Blood Marrow Transplant 2005, 11:161-168.
59. Déchanet J., Merville P., Lim A., et al. Implication of γδ T cells in the human immune response to cytomegalovirus. J Clin Invest 1999, 103:1437-1449.
60. Perko R., Kang G., Sunkara A., et al. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol Blood Marrow Transplant 2014, 21:130-136.
61. Godder K.T., Henslee-Downey P.J., Mehta J., et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007, 39:751-757.
62. Godfrey D.I., Hammond K.J., Poulton L.D., et al. NKT cells: facts, functions and fallacies. Immunol Today 2000, 21:573-583.
63. Rubio M., Moreira-Teixeira L., Bachy E., et al. Early posttransplantation donor-derived invariant natural killer T cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 2012, 120:2144-2154.
64. Williams K.M., Hakim F.T., Gress R.E. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007, 19:318-330.
65. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
66. Fu J., Heinrichs J., Yu X.Z. Helper T cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Arch Immunol Ther Exp 2014, 62:277-301.
67. Mold J.E., Venkatasubrahmanyam S., Burt T.D., et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science 2010, 330:1695-1699.
68. Azevedo R.I., Soares M.V., Albuquerque A.S., et al. Long-term immune reconstitution of naive and memory t cell pools after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:703-712.
69. Admiraal R., van Kesteren C., Jol-van der Zijde C.M., et al. Association between anti-thymocyte globulin (ATG) exposure and CD4+ immune reconstitution predicting overall survival in paediatric haematopoietic cell transplantation: a multicentre retrospective pharmacodynamic cohort analysis. Lancet Haematol 2015, 2:e194-e203. 10.1016/S2352-3026(15)00045-9.
70. Vignali D., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
71. Seddiki N., Santner-Nanan B., Martinson J., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
72. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
73. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257.
74. Rocha V., Wagner J.E., Sobocinski K.A., et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000, 342:1846-1854.
75. Rocha V., Cornish J., Sievers E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
76. Magenau J.M., Qin X., Tawara I., et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010, 16:907-914.
77. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
78. Guillaume T., Rubinstein D.B., Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998, 92:1471-1490.
79. Marie-Cardinea A., Divay F., Dutot I., et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol 2008, 127:14-25.
80. Comans-Bitter W.M., de Groot R., van den Beemd R., et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr 1997, 130:388-393.
81. Fujimaki K., Maruta A., Yoshida M., et al. Immune reconstitution assessed during five years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001, 27:1275-1281.
82. Chang X.J., Zhao X.Y., Huang X.J. Immune reconstitution after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:440-449.
83. Ball L.M., Lankester A.C., Bredius R.G., et al. Graft dysfunction and delayed immune reconstitution following haploidentical peripheral blood hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35(Suppl. 1):S35-S38.
84. de Lalla C., Rinaldi A., Montagna D., et al. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4 + and CD4- subset dynamics and correlates with remission state. J Immunol 2011, 186:4490-4499.
85. Lang P., Feuchtinger T., Teltschik H.M., et al. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant 2015, 50:S6-S10.
86. Bashey A., Zhang X., Sizemore C.A., et al. T cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013, 31:1310-1316.
87. Pérez-Martínez A., González-Vicent M., Valentín J., et al. Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. Bone Marrow Transplant 2012, 47:1419-1427.
88. Bertaina A., Merli P., Rutella S., et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood 2014, 124:822-826.
89. Airoldi I., Bertaina A., Prigione I., et al. γδ T cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes. Blood 2015, 125:2349-2358.
90. Pfeiffer M.M., Feuchtinger T., Teltschik H.M., et al. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica 2010, 95:1381-1388.
91. Kielsen K., Jordan K.K., Uhlving H.H., et al. T cell reconstitution in allogeneic haematopoietic stem cell transplantation: prognostic significance of plasma interleukin-7. Scand J Immunol 2015, 81:72-80.
92. Fujita A., Ihira M., Suzuki R., et al. Elevated serum cytokine levels are associated with human herpesvirus 6 reactivation in hematopoietic stem cell transplantation recipients. J Infect 2008, 57:241-248.
93. DiCarlo J., Agarwal-Hashmi R., Shah A., et al. Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 2014, 20:361-369.
94. Min C.K., Lee W.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:935-940.
95. Berger M., Signorino E., Muraro M., et al. Monitoring of TNFR1, IL-2Ra, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients. Bone Marrow Transplant 2013, 48:1230-1236.
96. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
97. Resende R.G., de Correia-Silva J., Silva T.A., et al. IL-17 Genetic and immunophenotypic evaluation in chronic graft-versus-host disease. Mediators Inflamm 2014, 571231.
98. Ponce D.M., Hildren P., Mumaw C., et al. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood 2015, 125:199-205.
99. Sakata N., Yasui M., Okamura T., et al. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001, 27:1153-1161.
100. Weber M., Stein P., Prüfer S., et al. Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease. Eur J Immunol 2014, 44:1857-1865.
101. Gluckman E. History of cord blood transplantation. Bone Marrow Transplant 2009, 44:621-626.
102. Talvensaari K., Clave E., Douay C., et al. A broad T cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002, 99:1458-1464.
103. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007, 369:1947-1954.
104. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
105. Hiwarkar P., Gaspar H.B., Gilmour K., et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013, 48:803-808.
106. Admiraal R., van Kesteren C., Jol-vanderZijde C.M., et al. Population pharmacokinetic modeling of Thymoglobulin® in children receiving allogeneic-hematopoietic cell transplantation (HCT): towards improved survival through individualized dosing. Clin Pharmacokinet 2014, 54:435-436.
107. Plantinga M., de Haar C., Nierkens S., Boelens J.J. Dendritic cell therapy in an allogeneic-hematopoietic cell transplantation setting: an effective strategy toward better disease control?. Front Immunol 2014, 5:218.
108. Sun Q., Burton R.L., Pollok K.E., et al. CD4 (+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol 1999, 195:81-88.
109. Park K.D., Marti L., Kurtzberg J., Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1Tcells from naive cord blood lymphocytes. Blood 2006, 108:1770-1773.